X0203 3/A 2009-09-02 2009-09-04 0 0001108205 CURIS INC CRIS 0001471556 Keegan Mitchell 45 MOULTON STREET CAMBRIDGE MA 02138 0 1 0 0 Vice-President Qualified stock option (right to buy) 1.35 2018-05-16 Common Stock 150000 D Qualified stock option (right to buy) .79 2018-10-24 Common Stock 18750 D Qualified stock option (right to buy) 1.07 2019-02-05 Common Stock 27500 D Options vest over a period of four years with 25% of the stock options vesting the first anniversary of the grant date, or May 16, 2009, and ad additional 6.25% of the shares during each successive three-month period therafter until the option is fully vested on the fourth anniversary of the grant date, or May 16, 2012, subject to continued employment. All stock options will expire 10 years from date of grant and the grand date for each option is 10 years prior to the expiration date. 103,125 of these options remain unvested as of September 2, 2009. Common stock subject to stock option award shall become exercisable on April 24, 2014 or upon the consummation of a collaboration, licensing or other similar agreement regarding the Targeted Cancer Drug Development Platform that includes an up-front cash payment of at least $10 million. For clarity, the cash payment shall be attributable to a nonrefundable license fee or other similar payment and shall not include an equity investment in Curis and any vesting is subject to continued service with the Curis. Options vest over a period of four years with 25% of the stock options vesting the first anniversary of the grant date, or February 5, 2010, and ad additional 6.25% of the shares during each successive three-month period therafter until the option is fully vested on the fourth anniversary of the grant date, or February 5, 2013, subject to continued employment. All stock options will expire 10 years from date of grant and the grand date for each option is 10 years prior to the expiration date. All of these options remain unvested as of September 2, 2009. Amanda M. Stastny, attorney-in-fact 2009-09-09